Prominent publications by Robert Louis Ferris

KOL Index score: 25936

BACKGROUND: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patient-reported outcomes (PROs).

METHODS: CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent ...

Known for Nivolumab Patients |  Cell Carcinoma |  Checkmate 141 |  Investigators Choice |  Metastatic Squamous
KOL Index score: 21644

IMPORTANCE: At many institutions, computed tomography with iodinated intravenous contrast medium is the preferred imaging modality for staging of the neck in squamous cell carcinoma of the head and neck. However, few studies have specifically assessed the diagnostic accuracy of computed tomography for determining the presence or absence of extracapsular spread (ECS).

OBJECTIVE: To determine the accuracy of modern, contrast-enhanced, multidetector computed tomography in the diagnosis of ...

Known for Computed Tomography |  Squamous Cell Carcinoma |  Extracapsular Spread |  Head Neck |  Presence Ecs
KOL Index score: 19185

BACKGROUND: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has shown evidence of additive activity in several tumor types. This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab ...

Known for Durvalumab Tremelimumab |  Squamous Cell |  Monoclonal Antibodies |  Metastatic Head |  Phase Iii
KOL Index score: 17766

PURPOSE: Tumor antigen-specific monoclonal antibodies (mAb) block oncogenic signaling and induce Fcγ receptor (FcγR)-mediated cytotoxicity. However, the role of CD8(+) CTL and FcγR in initiating innate and adaptive immune responses in mAb-treated human patients with cancer is still emerging.

EXPERIMENTAL DESIGN: FcγRIIIa codon 158 polymorphism was correlated with survival in 107 cetuximab-treated patients with head and neck cancer (HNC). Flow cytometry was carried out to quantify EGF ...

Known for Tumor Antigen |  Dendritic Cells |  Natural Killer |  Hnc Cetuximab |  Neck Cancer
KOL Index score: 17138

BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.

METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 ...

Known for Standard Therapy |  Cell Carcinoma |  Patients Nivolumab |  Neck Treatment |  Recurrent Squamous
KOL Index score: 15195

PURPOSE: Two modern methods of reirradiation, intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), are established for patients with recurrent or second primary squamous cell carcinoma of the head and neck (rSCCHN). We performed a retrospective multi-institutional analysis to compare methods.

METHODS AND MATERIALS: Data from patients with unresectable rSCCHN previously irradiated to ≥40 Gy who underwent reirradiation with IMRT or SBRT were ...

Known for Primary Head |  Imrt Sbrt |  Neck Cancer |  Local Neoplasms |  Rpa Class
KOL Index score: 15076

BACKGROUND: The authors hypothesized that histogenetic classification of salivary duct carcinoma (SDC) could account for de novo tumors and those with morphologic or molecular evidence (pleomorphic adenoma gene 1 [PLAG1], high-mobility group AT hook 2 [HMGA2] rearrangement, amplification) of pleomorphic adenoma (PA).

METHODS: SDCs (n = 66) were reviewed for morphologic evidence of PA. PLAG1 and HMGA2 alterations were detected by fluorescence in situ hybridization (FISH). PLAG1-positive ...

Known for Pleomorphic Adenoma |  Salivary Duct Carcinoma |  Situ Hybridization |  Morphologic Evidence Pa |  Plag1 Hmga2
KOL Index score: 15048

BACKGROUND: Fine-needle aspiration (FNA) cytology is a common approach to evaluating thyroid nodules, although 20% to 30% of FNAs have indeterminate cytology, which hampers the appropriate management of these patients. Follicular (or oncocytic) neoplasm/suspicious for a follicular (or oncocytic) neoplasm (FN/SFN) is a common indeterminate diagnosis with a cancer risk of approximately 15% to 30%. In this study, the authors tested whether the most complete next-generation sequencing (NGS) ...

Known for Thyroid Nodules |  Follicular Neoplasm |  Thyroseq V2 |  Fineneedle Carcinoma Carcinoma |  Oxyphilic Biopsy
KOL Index score: 15042

Immunotherapy with the EGFR-specific mAb cetuximab is clinically effective in 10–20% of patients with squamous cell carcinoma of the head and neck (SCCHN). Little information is available about the mechanism(s) underlying patients’ differential clinical response to cetuximab-based immunotherapy, although this information may contribute to optimizing the design of cetuximab-based immunotherapy. Our understanding of these mechanisms would benefit from the characterization of the variables ...

Known for Nk Cell |  Cetuximab Mediated |  Egfr Expression |  Monoclonal Antibodies |  Genetic Receptors
KOL Index score: 15027

PURPOSE: Locally recurrent head and neck squamous cell carcinoma can be treated with curative intent by surgical salvage or reirradiation with or without chemotherapy. We have previously demonstrated the feasibility and safety of stereotactic body reirradiation at our institution; however, efficacy has been unsatisfactory. Based on the successful combination of cetuximab with radiotherapy in locally-advanced squamous cell carcinoma of the head and neck, we compared stereotactic body ...

Known for Stereotactic Body Radiotherapy |  Squamous Cell |  Head Neck |  Concurrent Cetuximab |  Antibodies Monoclonal Antibodies
KOL Index score: 14705

Importance: Approximately 20% of fine-needle aspirations (FNA) of thyroid nodules have indeterminate cytology, most frequently Bethesda category III or IV. Diagnostic surgeries can be avoided for these patients if the nodules are reliably diagnosed as benign without surgery.

Objective: To determine the diagnostic accuracy of a multigene classifier (GC) test (ThyroSeq v3) for cytologically indeterminate thyroid nodules.

Design, Setting, and Participants: Prospective, blinded cohort study ...

Known for Indeterminate Cytology |  Thyroid Nodules |  Bethesda Iii |  Tumor Biopsy |  Multigene Genomic Classifier
KOL Index score: 14584

PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced progression within 6 months of platinum-containing chemotherapy.

PATIENTS AND METHODS: In the randomized, open-label, phase III CheckMate 141 trial, patients were randomized 2:1 to nivolumab 3 ...

Known for Prior Cetuximab |  Nivolumab Patients |  Squamous Cell |  Head Neck |  Antineoplastic Agents
KOL Index score: 14193

BACKGROUND: Extracapsular spread (ECS) in cervical lymph node metastases from head and neck squamous cell carcinoma (SCC) is regarded as an adverse prognostic factor and is often used to select patients who may benefit from adjuvant therapy. The prognostic value of ECS was evaluated for patients with oropharyngeal SCC (OPC; with known p16/human papillomavirus [HPV] status) and for patients with SCC of the oral cavity (OCC).

METHODS: Disease-specific survival (DSS) was assessed among SCC ...

Known for Extracapsular Spread |  Neck Carcinoma |  Papillomavirus Status |  Ecs Patients |  16 Humans
KOL Index score: 14103

IMPORTANCE: Positive margins are associated with poor prognosis among patients with oral tongue squamous cell carcinoma (SCC). However, wide variation exists in the margin sampling technique.

OBJECTIVE: To determine the effect of the margin sampling technique on local recurrence (LR) in patients with stage I or II oral tongue SCC.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective study was conducted from January 1, 1986, to December 31, 2012, in 5 tertiary care centers following tumor ...

Known for Tumor Bed |  Local Control |  Oral Tongue |  Positive Margins |  Squamous Cell
KOL Index score: 14073

OBJECTIVE/HYPOTHESIS: The utility of elective neck dissection in the management of patients with oral cavity and oropharyngeal cancer who present without neck metastases remains controversial. The study addressed the question of whether elective neck dissection improves regional control and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx presenting with T1/T2 node-negative disease.

STUDY DESIGN: A nonrandomized, uncontrolled retrospective chart ...

Known for Elective Neck Dissection |  Oral Cavity |  Squamous Cell Carcinoma |  Regional Control |  Patients Neck


Robert Louis Ferris: Influence Statistics

Sample of concepts for which Robert Louis Ferris is among the top experts in the world.
Concept World rank
cellular states icn #1
220 ptc #1
2 patients cbos #1
negative findings recurrence #1
phenotypic maturation lcdcs #1
nonsquamous cell cancers #1
95 tbm fragmentation #1
lrr female head #1
lrr ajcc8 pt2 #1
sbrt association #1
pairs tumor pairs #1
carotid dose #1
hnscc hgf #1
glis3 htt #1
response rates ici #1
clinical activity durvalumab #1
qrt pcr expression #1
patients treated hnscc #1
reviewdiscussion #1
qrtpcr automated analysis #1
70 positives #1
molecular assay dm #1
irradiation sbrt±cetuximab #1
oncologic outcomes tors #1
htt 220 ptc #1
killer cells head #1
rp2s #1
cytotoxicity parpi #1
head immunological cell #1
recurrence scchn #1
test thyroid nodules #1
lag3nc #1
observed overexpression hbd3 #1
gtube placement crt #1
increased tumor heterogeneity #1
ccr7 mediates #1
opc nonopc cases #1
tumor immunology role #1
vivo scid neoplasms #1
sbrt treatment rscchn #1
chemokine production attraction #1
attraction tumor infiltration #1
tim3 tumor immunotherapy #1
life late toxicities #1
sequential eua tors #1
promising salvage strategy #1
cd11bcd14hla #1
gsk3b axin1 #1
rp2s dlt #1
hnscc cetuximab treatment #1

Key People For Squamous Cell

Top KOLs in the world
Ahmedin M Jemal
united states breast cancer addis ababa
Freddie Ian Bray
cancer incidence nordic countries mortality rates
Jacques Ferlay
cancer incidence global burden latin america
Rebecca L Siegel
united states colorectal cancer incidence rates
William H Westra
human papillomavirus squamous cell head neck
Arlene A Forastiere
neck cancer squamous cell radiation therapy

Robert Louis Ferris:Expert Impact

Concepts for whichRobert Louis Ferrishas direct influence:Squamous cell,  Neck cancer,  Head neck,  Cell carcinoma,  Squamous cell carcinoma,  Neck neoplasms humans,  Human papillomavirus,  Neck squamous.

Robert Louis Ferris:KOL impact

Concepts related to the work of other authors for whichfor which Robert Louis Ferris has influence:Squamous cell,  Head neck,  Thyroid nodules,  Tumor microenvironment,  Human papillomavirus,  Cancer immunotherapy,  Immune checkpoint inhibitors.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA | Department of Otolaryngology, Hillman Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA;, | Department of Otolaryngolog

FREE Custom List